Rebif news blow against Merck KGaA

Merck KgaA has suffered a triple whammy in the last couple of days: First, Citibank and WestLB downgraded the company's stock. Then came news of a study showing that its MS drug Rebif performs no better than Teva Pharmaceuticals' Copaxone.

Meanwhile, some Israeli scientists have ID'd the genes that predict a positive response to Copaxone, opening the way for personalized treatment using the drug. Does that make it a quadruple whammy?

- see this Weizmann Institute of Science report on the Copaxone genes
- read about the market's response to Merck KGaA news

Related Articles:
Bayer outbids Merck KGaA for Schering. Report
Merck KGaA buying control of Serono. Report
Teva launches pivotal MS drug study. Report

Read more on: Merck KGaA | Teva

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.